ABMC — American Bio Medica Share Price
Last trade - 00:00- $0.00m
- $0.11m
- $0.91m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -154.9% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 3.87 | 3.65 | 4.15 | 2.22 | 0.91 | n/a | n/a | -28.58% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
American Bio Medica Corporation is a blank check company. The Company is exploring strategic transactions which may result in entering into a new line of business (subject to specific competitive limitations under the Asset Sale to Healgen).
Directors
- Last Annual
- December 31st, 2022
- Last Interim
- March 31st, 2023
- Incorporated
- April 10th, 1986
- Public Since
- October 27th, 1993
- No. of Employees
- 79
- Sector
- Holding Companies
- Industry
- Financials
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 48,098,476
- Address
- 122 Smith Rd, KINDERHOOK, 12106-2819
- Web
- https://abmc.com/
- Phone
- +1 5187588158
- Auditors
- UHY LLP
Upcoming Events for ABMC
Similar to ABMC
1399 Internet Technology Application
Pink Sheets on Nasdaq
VG Acquisition
Pink Sheets on Nasdaq
9 Meters Biopharma
Pink Sheets on Nasdaq
Absolute Health and Fitness
Pink Sheets on Nasdaq
ACC Aviation Holdings
Pink Sheets on Nasdaq
FAQ
As of Today at 01:13 UTC, shares in American Bio Medica are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in American Bio Medica last closed at $0.00 and the price had moved by -99.67% over the past 365 days. In terms of relative price strength the American Bio Medica share price has underperformed the S&P500 Index by -99.69% over the past year.
There is no consensus recommendation for this security.
Find out moreAmerican Bio Medica does not currently pay a dividend.
American Bio Medica does not currently pay a dividend.
American Bio Medica does not currently pay a dividend.
To buy shares in American Bio Medica you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in American Bio Medica had a market capitalisation of $0.00m.
Here are the trading details for American Bio Medica:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: ABMC
Based on an overall assessment of its quality, value and momentum American Bio Medica is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like American Bio Medica. Over the past six months, its share price has underperformed the S&P500 Index by -98.96%.
As of the last closing price of $0.00, shares in American Bio Medica were trading -99.98% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The American Bio Medica PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
American Bio Medica's management team is headed by:
- Melissa Waterhouse - CEO
- Lawrence Ferringo - VPR
- Jean Neff - SEC
- Peter Jerome - IND